Neoadjuvant endocrine therapy with or without palbociclib in low-risk patients: a phase III randomized double-blind SAFIA trial

BACKGROUND: The most prevalent subtype of breast cancer (BC) is luminal hormonal-positive breast cancer. The neoadjuvant chemotherapy regimens have side effects, emphasizing the need to identify new startegies. OBJECTIVE: Analyze the complete pathologic response (pCR) rate and overall response in a...

Descripción completa

Detalles Bibliográficos
Autores principales: Alsaleh, K., Al Zahwahry, H., Bounedjar, A., Oukkal, M., Saadeddine, A., Mahfouf, H., Bouzid, K., Bensalem, A., Filali, T., Abdel-Razeq, H., Larbaoui, B., Kandil, A., Abulkhair, O., Al Foheidi, M., Ghosn, M., Rasool, H., Boussen, H., Mezlini, A., Haddaoui, A., Ayari, J., Al Ghamdi, M., Errihani, H., Abdel-Aziz, N., Arafah, M., Dabouz, F., Bahadoor, M., Kullab, S., Nabholtz, J. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9864499/
https://www.ncbi.nlm.nih.gov/pubmed/36680581
http://dx.doi.org/10.1007/s00432-023-04588-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9864499/
https://www.ncbi.nlm.nih.gov/pubmed/36680581
http://dx.doi.org/10.1007/s00432-023-04588-3

Ejemplares similares